TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9987085

Group type: EXPERIMENTAL
Intervention: Intra-arterial norepinephrine (30 to 240 pmol/min)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (5 pmol/min)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Selective endothelin A (ETA) receptor antagonist BQ-123 (3 mg/hr)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Mixed endothelin-converting enzyme and neutral endopeptidase inhibitor phosphoramidon (30 nmol/min)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Selective neutral endopeptidase inhibitor thiorphan (30 nmol/min)
Number of subjects: 2
Study: 7503196

Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream
Number of subjects: 745

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 745
Study: 2106274

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.4 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Naloxone 0.05 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nalbuphine 20 mg
Number of subjects: 150
Study: 6444445

Group type: EXPERIMENTAL
Intervention: TSPA
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: FdUrd
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1613
Study: 29642094

Group type: EXPERIMENTAL
Intervention: SPS-MC (sodium picosulphate/magnesium citrate preparation)
Number of subjects: 341

Group type: COMPARATOR
Intervention: PEG-Asc+B (2-l ascorbic-acid-enriched polyethylene glycol solution plus bisacodyl pretreatment)
Number of subjects: 341
Study: 28514963

Group type: EXPERIMENTAL
Intervention: CHOICE intervention (multi-contact, extended counseling intervention)
Number of subjects: 304
Study: 26635229

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (diet and physical activity)
Number of subjects: 438

Group type: COMPARATOR
Intervention: PA only group (Happy 10 program)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Diet only group (nutrition education program)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 438
Study: 23345581

Group type: EXPERIMENTAL
Intervention: 3 doses of DNA vaccine (Advax) plus 1 dose of recombinant modified vaccinia virus Ankara (MVA) (TBC‐M4)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 3 doses of TBC‐M4 alone
Number of subjects: 32
Study: 21138518

Group type: EXPERIMENTAL
Intervention: Epoetin α (target Hb 9.5 to 11.0 g/dL and 11.5 to 13.0 g/dL)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 18640465

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/d
Number of subjects: 173

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 173
Study: 16717516

Group type: EXPERIMENTAL
Intervention: Pressure ulcer preventive dressing (PPD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thin-film dressing
Number of subjects: 30
Study: 12709347

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day orally for 7 days)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chloramphenicol (500 mg four times a day orally for 14 days)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 55
Study: 11215006

Group type: EXPERIMENTAL
Intervention: STOMP group (community-based antenatal care)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Control group (standard antenatal care)
Number of subjects: 1089
Study: 9003953

Group type: EXPERIMENTAL
Intervention: Serum alpha‐L‐fucosidase activity
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (healthy female patients)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CA 125
Number of subjects: 151
Study: 1469466

Group type: EXPERIMENTAL
Intervention: BCNU combined with vincristine intravenously and procarbazine orally, followed by radiation therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Surgery followed by radiation therapy
Number of subjects: 75
Study: 6367553

Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 21
Study: 29277099

Group type: EXPERIMENTAL
Intervention: Financial incentives up to $320/year for a minimum of 1 year
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 320
Study: 25747947

Group type: EXPERIMENTAL
Intervention: Indomethacin (I)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (M)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 92
Study: 24120857

Group type: EXPERIMENTAL
Intervention: Mild depressive symptoms
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Moderate depressive symptoms
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Severe depressive symptoms
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Depressive symptom severity
Number of subjects: 700
Study: 21161151

Group type: EXPERIMENTAL
Intervention: Percutaneous feeding tube (PEG tube)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No PEG tube (non-PEG group)
Number of subjects: 27
Study: 21211380

Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg once daily for 8 weeks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg once daily and Tolterodine 2 mg twice daily for 8 weeks
Number of subjects: 76
Study: 19183318

Group type: EXPERIMENTAL
Intervention: Facilitative educator talk during the DESMOND self‐management programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic educator talk during the DESMOND self‐management programme
Number of subjects: 0
Study: 16123895

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mebeverin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dietary treatment (fibre)
Number of subjects: 120
Study: 12860783

Group type: EXPERIMENTAL
Intervention: Advice nurse
Number of subjects: 1182

Group type: COMPARATOR
Intervention: On-call pediatrician
Number of subjects: 1182
Study: 12382386

Group type: EXPERIMENTAL
Intervention: 1% lidocaine (1 ml)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 1% lidocaine (2 ml)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (1 ml)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (2 ml)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 2% lidocaine (2 ml)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 132
Study: 10220941

Group type: EXPERIMENTAL
Intervention: TIVA (group 1, n = 41)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Balanced anaesthesia (group 2, n = 39)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both TIVA and balanced anaesthesia
Number of subjects: 80
Study: 7898814

Group type: EXPERIMENTAL
Intervention: Theory M nursing model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (three nursing units)
Number of subjects: 0
Study: 2135692

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7027892

Group type: EXPERIMENTAL
Intervention: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 12.5 mg, given as 2 tablets o.m.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg o.m. monotherapy
Number of subjects: 31
Study: 31735245

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Group Therapy (CBGT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 81
Study: 29177434

Group type: EXPERIMENTAL
Intervention: AZD4547 80 mg twice daily, orally, on a 2 weeks on/1 week off schedule of a 21-day cycle
Number of subjects: 71

Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m2 administered weekly on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both AZD4547 and paclitaxel
Number of subjects: 71
Study: 25528898

Group type: EXPERIMENTAL
Intervention: ESL 1,200 mg
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: ESL 800 mg
Number of subjects: 653

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 653
Study: 23450315

Group type: EXPERIMENTAL
Intervention: Self-administered Epworth Sleepiness Scale (ESSs)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Physician-administered Epworth Sleepiness Scale (ESSp)
Number of subjects: 225
Study: 21505942

Group type: EXPERIMENTAL
Intervention: Possession of a bonus booklet (BB)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Residents without a bonus booklet (BB)
Number of subjects: 242
Study: 19755930

Group type: EXPERIMENTAL
Intervention: Cell-mediated immunity (CMI) to diphtheria and tetanus toxoids and acellular pertussis antigens
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Proliferative response to vaccine antigens
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: CMI presence
Number of subjects: 167
Study: 17695378

Group type: EXPERIMENTAL
Intervention: Presence of intraventricular hemorrhage (IVH) in patients with SAH
Number of subjects: 3539

Group type: COMPARATOR
Intervention: Absence of intraventricular hemorrhage (IVH) in patients with SAH
Number of subjects: 3539
Study: 15188169

Group type: COMPARATOR
Intervention: High-dose interferon alpha (9 million units)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-dose interferon alpha (3 million units)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 11473558

Group type: EXPERIMENTAL
Intervention: s-ketamine (0.5 mg kg‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fentanyl (1.5 microg kg‐1)
Number of subjects: 90
Study: 11367689

Group type: EXPERIMENTAL
Intervention: recombinant alpha-2a interferon (1 million units daily for 6 days)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Vitamin B12 and Vitamin B1 (conventional dose for 6 days)
Number of subjects: 74
Study: 7836525

Group type: EXPERIMENTAL
Intervention: Laser-assisted micromanipulation (Er:YAG laser)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (Er:YAG laser)
Number of subjects: 0
Study: 3415884

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 5 ml in sitting position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 5 ml in lateral position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hyperbaric solution in sitting position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hyperbaric solution in lateral position
Number of subjects: 40
Study: 28873511

Group type: EXPERIMENTAL
Intervention: UC‐MSCs (1×10^6 UC‐MSCs/kg, four peripheral intravenous infusions, one infusion per week)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 82
Study: 27029459

Group type: EXPERIMENTAL
Intervention: 50-50% N2 O + i.v. remifentanil 0.1 μg/kg/min
Number of subjects: 21

Group type: COMPARATOR
Intervention: remifentanil 0.1 μg/kg/min
Number of subjects: 21
Study: 24941840

Group type: EXPERIMENTAL
Intervention: Shenkangling Decoction + Western medicine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 65
Study: 23234378

Group type: EXPERIMENTAL
Intervention: Information, motivation and behavioural skills (IMB) model intervention at School 1
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group at School 2
Number of subjects: 259
Study: 19548899

Group type: EXPERIMENTAL
Intervention: Surgical excision plus postoperative immunostimulation for 30 days with a natural product (STET)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Surgical excision alone (control group)
Number of subjects: 261
Study: 18482822

Group type: EXPERIMENTAL
Intervention: Photoelectric smoke alarms
Number of subjects: 643

Group type: COMPARATOR
Intervention: Ionizing smoke alarms
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Lithium batteries
Number of subjects: 643

Group type: COMPARATOR
Intervention: Carbon-zinc batteries
Number of subjects: 643
Study: 16454441

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/d)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 114
Study: 15060505

Group type: EXPERIMENTAL
Intervention: Ephedrine plus caffeine (25 mg ephedrine, 200 mg caffeine)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ephedrine alone (25 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine alone (200 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg) compared with ephedrine (25 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11011909

Group type: EXPERIMENTAL
Intervention: sibutramine plus orlistat
Number of subjects: 34

Group type: COMPARATOR
Intervention: sibutramine plus placebo
Number of subjects: 34
Study: 9362403

Group type: EXPERIMENTAL
Intervention: Low dose conjugated estrogen (1.25 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High dose conjugated estrogen (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 8
Study: 1543426

Group type: EXPERIMENTAL
Intervention: Baclofen (20mg for one week after titration)
Number of subjects: 30
Study: 3986438

Group type: EXPERIMENTAL
Intervention: Professional intervention
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Non-professional intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 3286657

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31029069

Group type: EXPERIMENTAL
Intervention: Synchronous PCI/CEA/CABG
Number of subjects: 43

Group type: COMPARATOR
Intervention: Synchronous CEA/CABG
Number of subjects: 43
Study: 28622115

Group type: EXPERIMENTAL
Intervention: Kochujang (32g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25160844

Group type: EXPERIMENTAL
Intervention: ULLS + EX (10 days of ULLS plus aerobic and resistance training)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ULLS + EX
Number of subjects: 19

Group type: COMPARATOR
Intervention: ULLS
Number of subjects: 19
Study: 23839316

Group type: EXPERIMENTAL
Intervention: Pediatric Airtraq(R)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional laryngoscope
Number of subjects: 34
Study: 21718212

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 189

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Citalopram (non-switched)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Desipramine (non-switched)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Switched patients (citalopram-desipramine and desipramine-citalopram)
Number of subjects: 189
Study: 19486341

Group type: EXPERIMENTAL
Intervention: Coffee (100 mg caffeine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 12
Study: 16982783

Group type: EXPERIMENTAL
Intervention: Itraconazole as NanoCrystal formulation (NCF) 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole as NanoCrystal formulation (NCF) 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Itraconazole as NCF (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole as NCF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Itraconazole as HPBCD solution (200 mg)
Number of subjects: 0
Study: 11966762

Group type: EXPERIMENTAL
Intervention: Chromium (200 microg) and Copper (3.0 mg) supplementation for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Copper (3.0 mg) supplementation for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chromium (200 microg) supplementation for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (0.394 g lactose)
Number of subjects: 40
Study: 10088136

Group type: EXPERIMENTAL
Intervention: Clonidine (0.5 and 2 micrograms/kg, orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: THA (25 and 50 mg, orally)
Number of subjects: 0
Study: 10150323

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 235

Group type: COMPARATOR
Intervention: Oral amitriptyline
Number of subjects: 235
Study: 1704168

Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg b.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Quinidine slow-release 800 mg b.i.d.
Number of subjects: 12
Study: 373262

Group type: EXPERIMENTAL
Intervention: Aldactone pro injectione (spironolactone)
Number of subjects: 30
Study: 31642087

Group type: EXPERIMENTAL
Intervention: Culturally informed education program to increase cultural competence in emergencies
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 200
Study: 30093510

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy with intracorporeal reconstruction (iRARC)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 320
Study: 27035460

Group type: EXPERIMENTAL
Intervention: Magnetically guided ultrasound (MGU) system
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional ultrasound (CU)
Number of subjects: 2
Study: 25019112

Group type: EXPERIMENTAL
Intervention: Vertical brushing method
Number of subjects: 49

Group type: COMPARATOR
Intervention: Horizontal brushing method
Number of subjects: 49
Study: 23738508

Group type: EXPERIMENTAL
Intervention: SYKFT plus irbesartan (SI regimen)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo plus irbesartan (PI regimen)
Number of subjects: 80
Study: 20598989

Group type: EXPERIMENTAL
Intervention: LOW-INR group (target INR 1.5-2.5)
Number of subjects: 396

Group type: COMPARATOR
Intervention: CONVENTIONAL-INR group (target INR 2.0-3.0)
Number of subjects: 396
Study: 18203083

Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 50
Study: 17067504

Group type: COMPARATOR
Intervention: Non-fractionated heparin (nFH) at 5-7 U/kg/hour
Number of subjects: 389

Group type: COMPARATOR
Intervention: Epoprostenol at 4-5 ng/kg/min
Number of subjects: 389

Group type: COMPARATOR
Intervention: Combined therapy of epoprostenol and nFH at 2.5 U/kg/hour
Number of subjects: 389
Study: 14575583

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (50 Gy) in the supraclavicular area and/or internal mammary area
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no radiotherapy)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (50 Gy) in patients with LN(+) >= 4
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no radiotherapy) in patients with LN(+) >= 4
Number of subjects: 162
Study: 11281369

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 15 mg per day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 20 mg per day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 30 mg per day
Number of subjects: 9
Study: 8894364

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 51
Study: 1860325

Group type: EXPERIMENTAL
Intervention: Conventional operative tracheostomy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Percutaneous tracheostomy
Number of subjects: 46
Study: 6750118

Group type: EXPERIMENTAL
Intervention: Indomethacin capsules (50 mg for the first 5 days, 100 mg for the second 5 days)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories (50 mg for the first 5 days, 100 mg for the second 5 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30739584

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 30676671

Group type: EXPERIMENTAL
Intervention: Bedtime music intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Audiobook control
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 57
Study: 30303192

Group type: EXPERIMENTAL
Intervention: Final Modified Tri‐Co system
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Tri‐Co scores
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Modified IDA scale
Number of subjects: 1008
Study: 27654816

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine as a primary sedative (n = 138; 11%)
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine as a secondary sedative (n = 280; 23%)
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine as a periextubation agent (n = 178; 15%)
Number of subjects: 2449

Group type: COMPARATOR
Intervention: Usual care (n = 1,224)
Number of subjects: 2449
Study: 24405345

Group type: EXPERIMENTAL
Intervention: Exam room teaching (n = 58)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conference room teaching (n = 64)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Exam room teaching
Number of subjects: 126
Study: 23067918

Group type: EXPERIMENTAL
Intervention: Low ABI (≤0.90)
Number of subjects: 2368

Group type: COMPARATOR
Intervention: High ABI (>1.3)
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Noncompressible ABI
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Normal ABI (0.91-1.3)
Number of subjects: 2368
Study: 19592211

Group type: EXPERIMENTAL
Intervention: Ventilator circuit change every 3 days
Number of subjects: 176

Group type: COMPARATOR
Intervention: Ventilator circuit change every 7 days
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 7-day circuit change
Number of subjects: 176
Study: 18990967

Group type: EXPERIMENTAL
Intervention: Tiotropium 8, 16, or 32 microg administered once daily via Respimat SMI for 14 days
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tiotropium 0.02, 0.04, 0.08, 0.16, 0.28, or 0.40 microg applied as two drops to one eye
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo administered in both studies
Number of subjects: 84